urosphere

News & events

Urosphere unveils its new web site

UROsphere is pleased to present its new web site that has been redesigned to offer enhanced functionality to better fit with our clients’ needs: Quick access to our assays, models and expertise A restricted area dedicated to our clients Personalized filter by disease area listing pertinent publications Subscribe to our RSS feed to receive our news updates Feel free to contact us with any questions or comments, we will be happy to assist you.

UROsphere to present scientific results at ICS annual meeting (San Francisco, 29th September – 3rd October 2009)

      The following posters will be presented: - Lluel P, Guerard M, Palea S, Julia-Guilloteau V. Duloxetine counteracts bladder overactivity induced by intravesical acetic acid in anesthetized female guinea-pigs through activation of 5-HT receptors. - Lluel P, Chene G, Dubourdeau M, Vergnolle N, Palea S, Coelho AM. Increase in arachidonic acid metabolites in the urine of female rats with cyclophosphamide-induced cystitis. UROsphere's top managers will be present during the...

UROsphere to present scientific results at AUA annual meeting (USA, 25-30 April 2009)

Following posters will be presented in different sessions: - Deba A, Lluel P, Palea S. Functional evidence of β3-adrenoceptors (β3-AR) in female mouse isolated urinary bladder. - Deba A, Palea S, Parini A, Lluel P. Differential gene expression in bladder hypertrophy following bladder outlet obstruction in mouse. - Lluel P, Guilloteau V, Guerard M, Pietra C, Lovati E, Palea S. Netupitant, a new selective NK1 receptor antagonist, reverses acetic acid-induced bladder overactivity in anesthetized...

UROsphere to present scientific results at EAU annual meeting (Stockholm, Sweden, 17-21 March , 2009)

UROsphere will take part in the European Association of Urology's Annual Meeting and present scientific results on BPH research: Gilles N, Lluel P, Rekik M, Guerard M, Palea S. AdTx1, a new peptidic α1-adrenoceptor antagonist with high affinity and selectivity for human α1A-adrenoceptor subtype: pharmacological characterization. The company's top managers will also present the company's expertise to members of the Medicon Valley biotech cluster (in Sweden and Denmark) in March 2009. To read...

UROsphere and Vectalys selected by the SISMIP for their research programme « Discovery of new targets for prostatic pathologies»

The 3SI program for Innovation in the Health Sector is a call for innovative projects reserved to SMEs located in Midi-Pyrenees Region. This program is also supported by the Regional Board of OSEO (France's national agency for industrial innovation), the Regional Board for Research and Technology (DRRT), the Cancer-Bio-Health cluster and Midi Pyrénées Innovation (MPI). UROsphere and Vectalys (a company specialized in viral vector production and cell transduction expertises for gene discovery...

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.